Good morning, HealthTech insiders. Who sets the standards for healthcare AI, and who is accountable when something goes wrong? CHAI’s latest governance spotlight brings that debate into hospitals, examining how oversight must continue after a tool enters care. Meanwhile, reporting on technology companies’ discussions with federal officials has put patient-record access under scrutiny: what should patients understand when they authorize an AI app to receive their medical information?
With comments due Monday, October 19, the FDA is also seeking input on how generative AI medical devices should be evaluated and monitored. Its discussion paper introduces no new rules, but raises consequential questions about evidence, risk and responsibility. From hospital workflows to consumer apps, today’s issue examines who keeps watch as healthcare AI moves into use.
In today's Signal:
AI governance after approval. CHAI’s Hartford HealthCare spotlight examines the work that continues after intake.
Patient records, patient choice. A follow-up on the access debate and the duties that depend on who receives the data.
The FDA deadline approaches. Comments on GenAI device evaluation are due October 19; the paper remains a discussion, not new rules.
In partnership with
The Best Marketing Angle You’ve Never Tried
Everyone wants a marketing hack that makes growing their business easier.
But according to business guru @MarketingMax (9 figures in attributable revenue delivered to clients), one of the best no-cost marketing hacks is finding the one angle that makes people foam at the mouth wanting what you sell.
Lucky for you @MarketingMax put together a quick 2-page Google Doc breaking down how to find yours in 10 minutes, with 20+ real examples you can steal from.
LATEST DEVELOPMENTS
CLINICAL AI GOVERNANCE
1. CHAI Puts the Focus on AI Governance Beyond the Initial Review
Rocco Orlando, Hartford HealthCare’s Strategic Advisor and Emeritus Chief Academic Officer, discusses AI governance beyond the initial review. Credit: CHAI / Hartford HealthCare.
CHAI’s October 15 governance spotlight features Hartford HealthCare’s Rocco Orlando and a practical question for health systems: how do you maintain oversight after an AI tool enters care? The account emphasizes continuing review and awareness of changes, rather than treating intake as the end of the process.
The details:
The inventory matters. Organizations need visibility into the AI reaching their workflows, including features supplied through existing vendors.
Shared review tools are evolving. CHAI released a draft intake playbook earlier this month for piloting; its voluntary tools can help organize evidence and local decisions.
Certification has a distinct role. The Joint Commission’s voluntary responsible-use certification assesses organizational processes; it is separate from FDA device authorization.
The Signal: The practical opportunity is to make oversight easier to maintain: a clear owner, an understandable record of the decision and a way to revisit it when the use changes.
PATIENT DATA & INTEROPERABILITY
2. Patient-Directed AI Record Access: What Providers Need to Get Right
Patient-directed access brings questions about data permissions, privacy and downstream use into focus. Illustrative image: HealthIT.gov.
Following the record-access debate covered yesterday, the next question is practical: what should patients understand when they send records to an AI application? KFF Health News’s October 9 investigation described industry efforts to shape access arrangements. Those requests should not be confused with enacted, unrestricted querying rights.
The details:
The recipient’s role changes the analysis. An independent app chosen by a patient and a vendor working for a provider can have different HIPAA responsibilities.
The liability distinction is specific. HHS says covered entities are not liable under HIPAA for an independent, patient-chosen app’s later use or disclosure when it is not a covered entity or business associate. That does not settle every form of legal liability.
Education can support access. Federal guidance permits accurate, objective and unbiased education about third-party app risks. Qualifying health apps may also face FTC breach-notification obligations.
The Signal: Make the relationship understandable. Patients should be able to identify who receives their records and how that service handles them, while providers support applicable access rights.
REGULATORY INTELLIGENCE
3. Monday Is the Deadline to Weigh In on FDA GenAI Device Evaluation
FDA Building 66, home to the Center for Devices and Radiological Health, in Silver Spring, Maryland. File photo: U.S. Food and Drug Administration.
The FDA is seeking comments by Monday, October 19, on its discussion paper about generative AI-enabled medical devices. For developers and clinicians, it is a chance to contribute concrete evidence about risk, evaluation and monitoring before the conversation moves further.
The details:
The docket is FDA-2026-N-7874. The agency welcomes focused responses; contributors do not need to answer every question.
The paper is exploratory. It is neither draft nor final guidance and does not propose or implement policy changes. Ideas about competence and risk are discussion topics, not an enacted software credential.
Related initiatives remain separate. FDA TEMPO lists specified intended uses under evaluation. CMS ACCESS has its own payment conditions; neither a pilot listing nor this consultation guarantees clearance or reimbursement.
The Signal: The most useful response will explain a real failure mode, the evidence needed to detect it and the limits of the proposed safeguard. That is more actionable than predicting a new approval system before one exists.
QUICK HITS
👀 WHAT WE'RE WATCHING NEXT
October 19: FDA GenAI comments. Watch for concrete input on evaluation and monitoring, followed by clearly identified agency next steps.
CHAI intake pilot. Watch whether a common evidence format reduces repeated review work while preserving local judgment.
Patient-access policy. Track published policy changes and permission practices, keeping industry proposals distinct from adopted requirements.
💰 FOLLOW THE MONEY
The deals:
OMass Therapeutics: $310M Series C (October 15). Co-led by Bain Capital Life Sciences, Forbion and Novo Holdings to advance small-molecule programmes in endocrinology and immunology. Announcement.
Abby Care: $82M financing (October 15). Led by Transformation Capital, with new healthcare investors backing expansion of its family-led home-care model and technology. Company announcement; founder confirms amount.
Scarlet: $50M Series B (October 12). Led by Headline to expand its AI and software medical-device certification business, including its US and Asia-Pacific footprint. Announcement.
The pattern: These rounds fund different needs: clinical development, care delivery and the infrastructure needed to bring medical software to market. The useful comparison is what each round enables next, not a claim that capital has abandoned one regulatory model for another..
📆 UPCOMING HEALTHTECH EVENTS
DTD2026 (October 26–27, Novotel München Messe, Munich): Digital transformation and medical technology. Dr. Dereck Mush speaks on October 27 about the gap between regulatory approval and adoption.
ARPA-H SURPASS Proposers Day (November 6, Washington, DC & virtual): Programme briefing for prospective proposers; registration is due October 28. Check the official event instructions.
HLTH USA (November 15–18, The Venetian Expo, Las Vegas): Healthcare innovation, care delivery, technology and investment..
🛠️ Trending HealthTech AI Tools
Cadence HypertensionOS: Listed in TEMPO for clinician-supervised, protocol-bound antihypertensive initiation and titration, with deterministic safety checks.
Limbic Unpacked: Listed for voice-based cognitive behavioral therapy within outpatient talking therapy, including an intended Medicare population.
Dexcom Glucose Health Program: Listed for metabolic monitoring and guidance using glucose and other health metrics with AI-supported insights..
🛠️ Trending HealthTech AI Startups
Onboard AI: Healthcare AI governance software connecting intake, assessment, review and continuing oversight. Product capabilities are company-described; no funding round is claimed here.
Abby Care: Combines family-caregiver training, clinical support and technology to support home-based care; announced new financing this week.
SonderMind: Behavioral health company whose SonderMind Adjunctive Care Application (SACA) appears in the TEMPO participant list.
DECISION INTELLIGENCE
Highlights: Deep Dives & Industry Reports
Where does your organization most need to strengthen its AI oversight?
That's it for today!
A purchasing decision, a patient’s permission and a regulatory submission each mark a beginning. The harder work follows: keeping track of what changes, understanding who is responsible and knowing when to act.
Healthcare AI will earn trust through that everyday work. The question for leaders is whether their systems make it easier to spot a problem and respond, or simply produce another document to file.
How did we do today?
See you tomorrow,
Dr. Dereck Mush, MD, MBA
The HealthTech Signal is independently funded. Sponsorships help us invest in better reporting, research, and a stronger newsletter for our readers. Want to reach HealthTech founders & executives while supporting the Signal? Get in touch.
Was this email forwarded to you? Sign up here.
Until tomorrow,
The HealthTech Signal